BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27048923)

  • 1. Erythema Multiforme-Like Bullous Pemphigoid.
    Imbernón-Moya A; Aguilar A; Burgos F; Gallego MÁ
    Actas Dermosifiliogr; 2016 Oct; 107(8):689-91. PubMed ID: 27048923
    [No Abstract]   [Full Text] [Related]  

  • 2. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.
    Schauer F; Kern JS; Virtic O; Technau-Hafsi K; Meiss F; Thoma K; Athanasiou I; Sitaru C; Di Zenzo G; Izumi K; Nishie W; Shimizu H; Bruckner-Tuderman L; Kiritsi D
    Br J Dermatol; 2019 Jan; 180(1):231-232. PubMed ID: 30188568
    [No Abstract]   [Full Text] [Related]  

  • 3. Bullous pemphigoid-like eruption subsequent to scabies: bullous scabies or bullous pemphigoid?
    Huang MX; Li ZS; Luo DQ; Lin Q
    G Ital Dermatol Venereol; 2015 Jun; 150(3):337-9. PubMed ID: 25658439
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bullous pemphigoid: diagnosis and therapy].
    Kneisel A; Hertl M
    Wien Med Wochenschr; 2014 Sep; 164(17-18):363-71. PubMed ID: 25077677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.
    Menzinger S; Kaya G; Schmidt E; Fontao L; Laffitte E
    Acta Derm Venereol; 2018 Feb; 98(2):284-286. PubMed ID: 29136264
    [No Abstract]   [Full Text] [Related]  

  • 6. Sensitivities and utility of non-invasive serological tests in the diagnosis of bullous pemphigoid.
    Yew YW; Tey HL
    Int J Dermatol; 2016 Sep; 55(9):e510-1. PubMed ID: 27028937
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination therapy of prednisolone and i.v. immunoglobulin treatment decreases circulating interleukin-5 and eosinophils in a patient with bullous pemphigoid.
    Yamashita C; Nakamizo S; Honda Y; Dainichi T; Kabashima K
    J Dermatol; 2017 Jan; 44(1):101-102. PubMed ID: 27154738
    [No Abstract]   [Full Text] [Related]  

  • 8. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.
    Fania L; Didona D; Pacifico V; Mariotti F; De Luca N; Abeni D; Mazzanti C; Di Zenzo G; Didona B
    J Dermatol; 2018 Sep; 45(9):1135-1140. PubMed ID: 30007013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
    Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
    J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
    Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
    J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis?
    Guilabert A; Lozano F; Iranzo P; Suárez-Casasús B; Martinez-De Pablo I; Julià M; Mascaró JM
    J Am Acad Dermatol; 2011 Nov; 65(5):1062-3. PubMed ID: 22000875
    [No Abstract]   [Full Text] [Related]  

  • 12. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
    Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
    Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
    Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
    Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
    [No Abstract]   [Full Text] [Related]  

  • 14. Type XVII collagen ELISA indices significantly decreased after bullous pemphigoid remission.
    Kusajima E; Akiyama M; Sato M; Natsuga K; Shimizu H
    Int J Dermatol; 2011 Feb; 50(2):238-40. PubMed ID: 21244398
    [No Abstract]   [Full Text] [Related]  

  • 15. Bullous pemphigoid masquerading as recurrent vesicular hand eczema.
    Veien NK
    Acta Derm Venereol; 2010; 90(1):4-5. PubMed ID: 20107717
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
    Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
    Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A severe course of bullous pemphigoid in a young man].
    Eigelshoven S; Bruch-Gerharz D; Enderlein E; Ruzicka T; Büchau AS; Hertl M; Reifenberger J; Schulte KW
    Hautarzt; 2006 Apr; 57(4):320-2. PubMed ID: 16523275
    [No Abstract]   [Full Text] [Related]  

  • 18. Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid.
    Delaumenie S; Assikar S; Prudhomme R; Matei I; Souyri N; Dalmay F; Bedane C
    Eur J Dermatol; 2019 Apr; 29(2):217-218. PubMed ID: 30734720
    [No Abstract]   [Full Text] [Related]  

  • 19. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin.
    Imanishi A; Tateishi C; Imanishi H; Sowa-Osako J; Koga H; Tsuruta D; Hashimoto T
    J Dermatol; 2015 Apr; 42(4):394-7. PubMed ID: 25708520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peristomal bullous pemphigoid.
    Marzano AV; Vezzoli P; Colombo A; Serini SM; Crosti C; Berti E
    J Dermatol; 2010 Sep; 37(9):840-2. PubMed ID: 20883375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.